FSC231
Based on 1 Customer Validation
FSC231 is a PSD‐95/DLG/ZO‐1 (PDZ) domain inhibitor of PICK1. FSC231 has analgesic effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.51%
- CAS. Nr.: 1215849-96-9
- Formel: C13H10Cl2N2O3
- Molecular Weight:313.14
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Covalent Screening Library
HY-L036
-
Anti-diabetic Compound Library
HY-L040
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Neuroprotective Compound Library
HY-L070
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Antidepressant Compound Library
HY-L108
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cysteine Targeted Covalent Library
HY-L153
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Alle iGluR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
PICK1[1].
FSC231 (50 μM) blocks binding between GluR2 and PICK1 in COS7 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
FSC231 (39.2μg/kg/day, i.p., for 4 weeks) inhibits the development of diabetic cardiomyopathy in rats by inhibiting ROS generation and apoptosis partly via PICK1/eNOS/cGMP pathway[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Paclitaxel (HY-B0015)‐induced neuralgia of rats[1]
-
Dosage:78.40 μg/kg in total
-
Administration:i.p., daily, seven times, completed at 3 h before Paclitaxel
-
Result:Reversed the changes of inflammatory cytokines (IL‐6, TNF‐α and IL‐10).
Inhibited the phosphorylation levels of GSK‐3β and ERK1/2.
Chemical Information
-
CAS. Nr. 1215849-96-9
-
Appearance Solid
-
Molecular Weight 313.14
-
Formel C13H10Cl2N2O3
-
Color White to off-white
-
SMILES
O=C(OCC)NC(/C(C#N)=C/C1=CC=C(Cl)C(Cl)=C1)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (159.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Zhang X, et al. FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3β and ERK1/2. Brain Behav. 2021 Nov;11(11):e2380. [Content Brief]
[2]. Thorsen TS, et al. Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):413-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1935 mL | 15.9673 mL | 31.9346 mL | 79.8365 mL |
| 5 mM | 0.6387 mL | 3.1935 mL | 6.3869 mL | 15.9673 mL | |
| 10 mM | 0.3193 mL | 1.5967 mL | 3.1935 mL | 7.9836 mL | |
| 15 mM | 0.2129 mL | 1.0645 mL | 2.1290 mL | 5.3224 mL | |
| 20 mM | 0.1597 mL | 0.7984 mL | 1.5967 mL | 3.9918 mL | |
| 25 mM | 0.1277 mL | 0.6387 mL | 1.2774 mL | 3.1935 mL | |
| 30 mM | 0.1064 mL | 0.5322 mL | 1.0645 mL | 2.6612 mL | |
| 40 mM | 0.0798 mL | 0.3992 mL | 0.7984 mL | 1.9959 mL | |
| 50 mM | 0.0639 mL | 0.3193 mL | 0.6387 mL | 1.5967 mL | |
| 60 mM | 0.0532 mL | 0.2661 mL | 0.5322 mL | 1.3306 mL | |
| 80 mM | 0.0399 mL | 0.1996 mL | 0.3992 mL | 0.9980 mL | |
| 100 mM | 0.0319 mL | 0.1597 mL | 0.3193 mL | 0.7984 mL |
FSC231 Related Classifications
HY-117772 Related Classifications
Powered by Bioz